Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, shared a post on X:
“Now enrolling MD Anderson Cancer Center: IVORY trial of ivonescimab (first-in-class PD1×VEGF bispecific) in metastatic clear cell Kidney Cancer after prior IO±TKI. Hypothesis: Cooperative inhibition of PD1/VEGF signaling will restore treatment sensitivity.”
More posts featuring Pavlos Msaouel.